Chinese and foreign pharmaceutical companies compete to lay out the out-of-hospital market, how can domestic pharmaceutical companies remain competitive?

In recent years, under the background of mining, the pharmaceutical industry has under changed greatly.
major pharmaceutical companies patent expired drugs to get the 'luxury version' price is no longer realistic.
, followed by the major pharmaceutical companies have started a strategy, business strategy transformation adjustment.
pharmaceutical companies compete to lay out outside the hospital, how to improve the competitiveness of domestic pharmaceutical companies (Photo: Pharmaceutical Network) Among them, the out-of-hospital market has become a new battleground for many pharmaceutical companies to compete for market share.
Such as Pfizer in the third batch after the bid, has done a re-analysis of the relevant strategy, but also made a "one product, two regulations three dosage form" strategy, with the intention of helping hospitals to establish a reasonable drug catalog.
addition, multinational pharmaceutical companies such as Bayer and AstraZeneta have set up dedicated marketing teams aimed at grass-roots markets and prescription outflows.
in the prescription outflow market, the chain of pharmacies, DTP pharmacies known for its specialized services, is the choice of many multinational pharmaceutical companies.
, as the undertaker of prescription exoded, the growth rate of prescription drugs in the out-of-hospital market has been increasing in recent years, and has been maintaining a high rate of growth.
this development trend, Chinese and foreign pharmaceutical companies are beginning to compete for layout, that in the face of more and more fierce market competition, how can domestic pharmaceutical companies in the off-site market to enhance and maintain competitiveness? The construction of Internet channels from the "4 plus 7" volume procurement model, many pharmaceutical companies began to accelerate the search for out-of-hospital distribution of the way out.
Industry insiders say that in the context of a large number of prescriptions and drugs are flowing out of public hospitals, some pharmaceutical companies are focusing on the development of Internet hospital business, just from online and offline to undertake the outflow of prescriptions and drug circulation.
china's prescription exoded market should exceed 600 billion by 2020, according to public data, which is undoubtedly a good thing for Internet medical companies or pharmaceutical e-commerce platforms.
Internet sales model, although temporarily unable to completely replace the traditional play, but it is a good complement to offline channels, so that drugs can reach more places in a shorter period of time, but also enable pharmaceutical companies to expand sales channels.
, domestic pharmaceutical companies in the layout of the off-site market will be combined with Internet medical care, or there will be more possibilities for development.
layout of large varieties, high-margin slow disease drug species selection for out-of-hospital prescription drug marketing is both the foundation and the first step.
price is too low, lack of space varieties regardless of the hospital outside the hospital is difficult to obtain channel platform respect, and not as long as there is a fee, no matter what medicine can be sold.
From the current layout of pharmaceutical companies, to cardiovascular, diabetes, respiratory and other representative of the chronic disease varieties, and tumors, immune inflammation as the representative of the high-margin space of specialized drug species, as well as unique varieties, Chinese medicine species, will probably be out-of-hospital prescriptions worth tapped potential areas.
in fact, this kind of drugs have a characteristic, is a large number of prescriptions, many kinds.
the construction and management of professional marketing team in the long run, with the volume of procurement varieties will gradually expand, involving more and more categories.
pharmaceutical companies urgently need to expand potential out-of-hospital channels, as a strong grasp of market share.
, pharmacy purchase channels will be broadened, and the variety of sales will be more diversified.
process, direct docking production enterprises, and professional services more powerful industry - DTP pharmacies are more likely to take on the good.
this situation, the construction and management of the DTP marketing team of pharmaceutical companies will become critical.
but it's worth noting that the shift in marketing teams is really a very difficult transition for pharmaceutical companies, because it's very difficult for people to change.
the larger the enterprise, the stronger the product force, the greater the transformation may be.
AZ (AstraZenecom) is one of the more successful companies in the pharmaceutical industry to transform DTP, which is characterized by "good products" and "firmness" - the company to the transformation of the system set up, rewards and training to set up a rigorous and careful plan.